ArticleJournal of neuro-oncology2009
Evaluation of neo-angiogenesis in a case of chordoid meningioma.
Article in Journal of neuro-oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 15 citations in OpenAlex.
- Role of bevacizumab for treatment-refractory meningiomas: A systematic analysis and literature review.Surgical neurology international · 2018Review
- Perfusion computed tomography of intracranial meningiomas: In vivo correlation of cerebral blood volume and vascular permeability.The neuroradiology journal · 2015Article
- Chordoid meningioma: a retrospective series of seven consecutive cases.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2013Article
- Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series.Journal of neuro-oncology · 2012Article
- Chordoid meningioma in a patient with lymphangioleiomyomatosis.Journal of neuro-oncology · 2011Article
- Angiogenesis as a predictor of recurrence in meningiomas.Journal of neuro-oncology · 2011Article
- Chordoid meningioma: a clinicopathologic study of 11 cases at a single institution.Journal of neuro-oncology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chordoid is a rare variant of meningioma that displays a high recurrence rate. In this study we evaluated the immunohistochemical expression of factors that regulate the neo-angiogenesis process in a case of chordoid meningioma with an adverse clinical course. A high microvessel density (MVD), as well as high VEGF and VEGF-R1 expression, was encountered in this tumor. By contrast, the anti-angiogenic factor semaphorin3A, highly expressed in this chordoid meningioma, was ineffective because of the absence of its receptor neuropilin-1. We suggest that VEGF expression and MVD may represent significant prognostic factors in chordoid meningiomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.